Cemiplimab shows promising early outcomes for advanced cutaneous squamous-cell carcinoma
- Posted on: Jul 13 2018
- Leave a response
This open-label multicenter study evaluated the human monoclonal antibody, cemiplimab, for treatment of advanced cutaneous squamous-cell carcinoma. Cemiplimab is a high-affinity monoclonal antibody directed against programmed death 1 (PD-1).
Source: AAO
Posted in: Uncategorized